Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans

Autoři

YU Tianzhou JIN Shihan CHANG Li CHAMBERS James D. HLÁVKA Jakub

Rok publikování 2023
Druh Článek v odborném periodiku
Časopis / Zdroj BIODRUGS
Citace
www https://link.springer.com/article/10.1007/s40259-023-00593-7
Doi http://dx.doi.org/10.1007/s40259-023-00593-7
Popis Background Biosimilars have been introduced with the goal of competing with high-priced biologic therapies, yet their adoption has been slower than expected and resulted in limited efficiency gains. We aimed to explore factors associated with biosimilar coverage relative to their reference products by commercial plans in the United States (US).

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.